Tags

Type your tag names separated by a space and hit enter

Human β-defensin-2 as a marker for disease severity and skin barrier properties in atopic dermatitis.
Br J Dermatol. 2013 Sep; 169(3):587-93.BJ

Abstract

BACKGROUND

Skin infections related to disrupted antimicrobial defence are a common problem in atopic dermatitis (AD). Altered levels of antimicrobial peptides, including human β-defensin (hBD)-2, have been reported in AD skin, and a link to impaired barrier function has been suggested.

OBJECTIVES

To study hBD-2 in relation to skin barrier function in patients with AD and controls, and to study hBD-2 in relation to disease severity.

METHODS

Twenty-five patients with AD and 11 controls were enrolled. hBD-2 peptide concentration was determined in stratum corneum samples collected by a minimally invasive tape-stripping method. Disease severity was assessed by SCORing Atopic Dermatitis (SCORAD), and skin barrier function was evaluated by measurement of transepidermal water loss (TEWL) and skin pH. Patients with AD were characterized according to filaggrin mutations.

RESULTS

hBD-2 concentrations in the stratum corneum were found to differ between lesional and nonlesional AD skin and controls, with the highest values in lesional skin (P < 0·001). SCORAD and TEWL were significantly increased in participants with measureable hBD-2 (P < 0·018 and P < 0·007, respectively). Significant correlations between hBD-2 in lesional skin, and TEWL and SCORAD were observed (R = 0·55 and R = 0·44, respectively). No correlations with skin pH were found. hBD-2 was not found to relate to filaggrin mutations.

CONCLUSIONS

A significant correlation was found between hBD-2, disturbed skin barrier function and disease severity. The minimally invasive skin sample technique enables evaluation of the stratum corneum and its proteins over time and provides the possibility of relating these findings to treatment, infections and physiological variations.

Authors+Show Affiliations

Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, 2400, Copenhagen NV, Denmark.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23647067

Citation

Clausen, M-L, et al. "Human Β-defensin-2 as a Marker for Disease Severity and Skin Barrier Properties in Atopic Dermatitis." The British Journal of Dermatology, vol. 169, no. 3, 2013, pp. 587-93.
Clausen ML, Jungersted JM, Andersen PS, et al. Human β-defensin-2 as a marker for disease severity and skin barrier properties in atopic dermatitis. Br J Dermatol. 2013;169(3):587-93.
Clausen, M. L., Jungersted, J. M., Andersen, P. S., Slotved, H. C., Krogfelt, K. A., & Agner, T. (2013). Human β-defensin-2 as a marker for disease severity and skin barrier properties in atopic dermatitis. The British Journal of Dermatology, 169(3), 587-93. https://doi.org/10.1111/bjd.12419
Clausen ML, et al. Human Β-defensin-2 as a Marker for Disease Severity and Skin Barrier Properties in Atopic Dermatitis. Br J Dermatol. 2013;169(3):587-93. PubMed PMID: 23647067.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Human β-defensin-2 as a marker for disease severity and skin barrier properties in atopic dermatitis. AU - Clausen,M-L, AU - Jungersted,J M, AU - Andersen,P S, AU - Slotved,H-C, AU - Krogfelt,K A, AU - Agner,T, PY - 2013/04/30/accepted PY - 2013/5/8/entrez PY - 2013/5/8/pubmed PY - 2014/5/16/medline SP - 587 EP - 93 JF - The British journal of dermatology JO - Br. J. Dermatol. VL - 169 IS - 3 N2 - BACKGROUND: Skin infections related to disrupted antimicrobial defence are a common problem in atopic dermatitis (AD). Altered levels of antimicrobial peptides, including human β-defensin (hBD)-2, have been reported in AD skin, and a link to impaired barrier function has been suggested. OBJECTIVES: To study hBD-2 in relation to skin barrier function in patients with AD and controls, and to study hBD-2 in relation to disease severity. METHODS: Twenty-five patients with AD and 11 controls were enrolled. hBD-2 peptide concentration was determined in stratum corneum samples collected by a minimally invasive tape-stripping method. Disease severity was assessed by SCORing Atopic Dermatitis (SCORAD), and skin barrier function was evaluated by measurement of transepidermal water loss (TEWL) and skin pH. Patients with AD were characterized according to filaggrin mutations. RESULTS: hBD-2 concentrations in the stratum corneum were found to differ between lesional and nonlesional AD skin and controls, with the highest values in lesional skin (P < 0·001). SCORAD and TEWL were significantly increased in participants with measureable hBD-2 (P < 0·018 and P < 0·007, respectively). Significant correlations between hBD-2 in lesional skin, and TEWL and SCORAD were observed (R = 0·55 and R = 0·44, respectively). No correlations with skin pH were found. hBD-2 was not found to relate to filaggrin mutations. CONCLUSIONS: A significant correlation was found between hBD-2, disturbed skin barrier function and disease severity. The minimally invasive skin sample technique enables evaluation of the stratum corneum and its proteins over time and provides the possibility of relating these findings to treatment, infections and physiological variations. SN - 1365-2133 UR - https://www.unboundmedicine.com/medline/citation/23647067/Human_β_defensin_2_as_a_marker_for_disease_severity_and_skin_barrier_properties_in_atopic_dermatitis_ L2 - https://doi.org/10.1111/bjd.12419 DB - PRIME DP - Unbound Medicine ER -